(Reuters) -The European Union's health regulator has lifted the temporary restriction on the use of French drugmaker Valneva's chikungunya vaccine, Ixchiq,...
17 hours ago

The recommended pause for use in people ages 60 and older follows a CDC alert in early March that said it was investigating five...
2 months ago

Other authorities are expected to mirror the European Medicines Agency's decision to lift the temporary restriction it placed on using...
2 days ago

Valneva successfully expands access to Asia for its Chikungunya Vaccine with Serum Institute of India.
7 months ago

Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that...
1 week ago

Valneva said the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating individuals aged 65 and above with...
6 days ago

The Food and Drug Administration and Centers for Disease Control and Prevention to recommend suspending use of Valneva's chikungunya vaccine in people at least...
2 months ago

Two chikungunya vaccines are available in the United States: a live-attenuated vaccine (IXCHIQ) and a virus-like particle vaccine (VIMKUNYA)...
2 months ago

France's public health agency, the Haute Autorité de Santé (HAS), has temporarily suspended the use of Valneva's vaccine Ixchiq in adults ages 65 years and...
2 months ago

Valneva (NASDAQ:VALN) said on Friday that the European Medicines Agency (EMA) has lifted the suspension on its chikungunya vaccine, Ixchiq,...
1 week ago